This review concluded that moxifloxacin-based triple therapy was more effective and did not increase the incidence of overall side effects compared with clarithromycin-based triple therapy in the treatment of Helicobacter pylori infection. These conclusions are supported by the results presented, but should be interpreted with some degree of caution due to the possibility of publication bias and small number of generally poor quality trials.
Searching
The Cochrane Library, PubMed, EMBASE, Science Citation Index Expanded, and Chinese Biomedical Literature Databases were searched to December 2008. Search terms were reported. References of retrieved studies were screened. No language restrictions were applied.
Study selection
Randomised controlled trials (RCTs) that compared moxifloxacin-based triple therapy (amoxicillin or nitroimidazoles plus proton pump inhibitor) with clarithromycin-based triple therapy in patients with Helicobacter pylori (H. pylori) infection were eligible for inclusion. Trials had to report confirmation of infection eradication at least four weeks after treatment completion based on urea breath testing, or gastric mucosal biopsy for histology, or culture.
Included trials were conducted in China, Croatia, Italy and Turkey. Triple therapy regimes included tinidazole, amoxicillin, lansoprazole, esomeprazole, metronidazole, omeprazole or ranitidine bismuth citrate in addition to moxifloxacin or clarithromycin. Most trials included H. pylori positive patients with non-ulcer dyspepsia; one study included H. pylori positive adults. Treatment duration was one week in all but one trial (which was two weeks). Most trials confirmed eradication using the urea breath test; one trial used histology. Eradication was assessed after four to eight weeks follow-up.
The authors did not state how many reviewers selected studies for inclusion.
Assessment of study quality
Two reviewers independently assessed trial quality using the Jadad criteria which assessed randomisation, blinding and description of withdrawals and drop-outs. Trials were assigned a score out of 5 points. Concealment of treatment allocation was also assessed. Disagreements were resolved through consensus.
Data extraction
Two reviewers independently extracted data on the number of patients in which infection eradication was confirmed, and the number of patients with side effects in the intervention and control groups. These data were combined with data on the number of participants in each group to estimate relative risks (RR). Data were extracted on an intention-to-treat basis.
Methods of synthesis
Summary relative risks and 95% confidence intervals (CIs) were estimated using the DerSimonian and Laird model, which the authors described as a fixed-effect model. Heterogeneity was assessed using the I 2 statistic.
